Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation

Table 1

Cumulative probability and RR of losing or gaining visual acuity.

Parameters	Predominantly classic	Minimally classic	Occult with no classic
Cumulative probability of change in vision
Usual care at 1 year
Gain of >3 lines	2.41%	1.92%	2.17%
Loss of 3–6 lines	23.10%	28.85%	22.83%
Loss of >6 lines	29.14%	16.35%	32.61%
Usual care at 2 years
Gain of >3 lines	1.48%	2.89%	1.71%
Loss of 3–6 lines	6.33%	6.33%	6.33%
Loss of >6 lines	4.21%	10.57%	14.13%
PDT at 1 year
Gain of >3 lines	5.66%	6.44%	3.01%
Loss of 3–6 lines	26.51%	27.23%	28.92%
Loss of >6 lines	13.46%	16.83%	22.29%
PDT at 2 years
Gain of >3 lines	1.75%	1.98%	1.81%
Loss of 3–6 lines	6.35%	5.44%	8.16%
Loss of >6 lines	3.00%	2.97%	6.63%
RR of ranibizumab versus PDT
at 1 year
Gain of >3 lines	7.2	N/A	N/A
Loss of 3–6 lines	0.1	N/A	N/A
Loss of >6 lines	0	N/A	N/A
at 2 years
Gain of >3 lines	0.49	N/A	N/A
Loss of 3–6 lines	4.35	N/A	N/A
Loss of >6 lines	0.06	N/A	N/A
RR of ranibizumab versus usual care
at 1 year
Gain of >3 lines	N/A	6.69	6.69
Loss of 3–6 lines	N/A	0.17	0.17
Loss of >6 lines	N/A	0.09	0.09
at 2 years
Gain of >3 lines	N/A	0.42	0.42
Loss of 3–6 lines	N/A	3.78	3.78
Loss of >6 lines	N/A	0.14	0.14
RR of bevacizumab versus ranibizumab
at 1 and 2 years
Gain of >3 lines	0.92	0.92	0.92
Loss of 3–6 lines	1.07	1.07	1.07
Loss of >6 lines	1.07	1.07	1.07

RR: risk ratio.
N/A: not applicable.